It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Coatomer complex I (COPI) mediates retrograde vesicular trafficking from Golgi to the endoplasmic reticulum (ER) and within Golgi compartments. Deficiency in subunit alpha causes COPA syndrome and is associated with type I IFN signalling, although the upstream innate immune sensor involved was unknown. Using in vitro models we find aberrant activation of the STING pathway due to deficient retrograde but probably not intra-Golgi transport. Further we find the upstream cytosolic DNA sensor cGAS as essentially required to drive type I IFN signalling. Genetic deletion of COPI subunits COPG1 or COPD similarly induces type I IFN activation in vitro, which suggests that inflammatory diseases associated with mutations in other COPI subunit genes may exist. Finally, we demonstrate that inflammation in COPA syndrome patient peripheral blood mononuclear cells and COPI-deficient cell lines is ameliorated by treatment with the small molecule STING inhibitor H-151, suggesting targeted inhibition of the cGAS/STING pathway as a promising therapeutic approach.
Mutations in the coatomer complex I can result in endoplasmic reticulum stress and inflammatory consequences. Here authors define aberrant activation of the STING immunosensing pathway in a disturbed coatmer complex context and the therapeutic modulation of this axis to counter the associated immunopathology.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details












1 Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Institute of Structural Biology, University Hospital Bonn, Bonn, Germany (GRID:grid.15090.3d) (ISNI:0000 0000 8786 803X)
2 Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
3 Centre for Autoinflammatory Diseases and Primary Immunodeficiencies, IRCCS Istituto Giannina Gaslini, Genoa, Italy (GRID:grid.419504.d) (ISNI:0000 0004 1760 0109)
4 University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889)
5 Inflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); Monash Biomedicine Discovery Institute, Monash University, Department of Anatomy and Developmental Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
6 University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Advanced Technology and Biology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889)
7 Center for Dynamic Imaging, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889)
8 Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany (GRID:grid.15090.3d) (ISNI:0000 0000 8786 803X); Institute of Immunology, Philipps-University Marburg, BMFZ, Marburg, Germany (GRID:grid.10253.35) (ISNI:0000 0004 1936 9756)
9 Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany (GRID:grid.15090.3d) (ISNI:0000 0000 8786 803X); German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany (GRID:grid.452463.2)
10 Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Australia (GRID:grid.452824.d); Monash University, Department of Molecular and Translational Science, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
11 Institute of Structural Biology, University Hospital Bonn, Bonn, Germany (GRID:grid.15090.3d) (ISNI:0000 0000 8786 803X)
12 Centre for Autoinflammatory Diseases and Primary Immunodeficiencies, IRCCS Istituto Giannina Gaslini, Genoa, Italy (GRID:grid.419504.d) (ISNI:0000 0004 1760 0109); University of Genoa, Genoa, Italy (GRID:grid.5606.5) (ISNI:0000 0001 2151 3065)